Infex Reports Phase IIa Win for Anti-Pseudomonas Antibody

Why It Matters

RESP‑X could fill a critical gap by directly disarming chronic Pseudomonas infection, potentially reducing exacerbations and antibiotic pressure in a high‑risk bronchiectasis population. Its success would broaden the therapeutic arsenal beyond anti‑inflammatory agents, reshaping standard care pathways.

Key Takeaways

• Phase IIa trial shows RESP‑X safe, well tolerated.
• Quarterly dosing feasible due to 28.8‑day half‑life.
• Early efficacy signal: fewer exacerbations, P=0.08.
• Targets PcrV virulence protein, not bacterial killing.
• Adds anti‑virulence option alongside brensocatib and inhaled antibiotics.

Pulse Analysis

The treatment landscape for non‑cystic fibrosis bronchiectasis is evolving rapidly. Historically, management has centered on symptom control and broad‑spectrum inhaled antibiotics, with the 2025 FDA approval of brensocatib marking the first disease‑modifying therapy that dampens neutrophilic inflammation. However, chronic colonisation by Pseudomonas aeruginosa remains a major driver of exacerbations, hospitalisations, and lung function decline, underscoring a persistent need for infection‑directed interventions that do not rely on conventional antibiotics.

Infex Therapeutics’ RESP‑X introduces a novel anti‑virulence approach by targeting the PcrV component of the bacterial Type 3 Secretion System. By neutralising this key toxin‑delivery mechanism, the humanised IgG4 antibody aims to reduce tissue damage while preserving the microbiome, potentially lowering selective pressure for resistance. The Phase IIa trial demonstrated a clean safety profile, no infusion reactions, and pharmacokinetics compatible with quarterly administration—a practical schedule for chronic disease management. Although the efficacy signal did not reach conventional significance, the reduction in exacerbations over a six‑month window suggests a clinically meaningful trend that warrants further investigation.

If subsequent pivotal studies confirm efficacy, RESP‑X could occupy a complementary niche alongside brensocatib and inhaled antibiotics, offering clinicians a targeted tool to mitigate Pseudomonas‑driven disease progression. The anti‑virulence strategy also aligns with broader industry shifts toward precision biologics that modulate pathogen behaviour rather than eradicate microbes outright. Successful regulatory approval would not only expand therapeutic options for bronchiectasis patients but also validate a new paradigm for tackling chronic bacterial colonisation across respiratory diseases.